Login to Your Account

Regulatory NEWS

In an effort to advance regulatory science and bring the clinical trial process into the 21st century, the FDA is looking at a trade-off with sponsors – more engagement with agency staff on complex innovative trial designs in exchange for more public disclosure about what goes into those designs and how they work.

HONG KONG – Looking to improve regulatory coordination and supervision of drug and food markets, the Chinese government may merge together several agencies – including the China FDA (CFDA) – into an umbrella State Drug Administration (SDA) with national scope.

Despite warnings of unintended consequences, the U.S. House could take another step this week toward making right-to-try legislation the law of the land.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: